U.S. FDA approves Biogen's hemophilia A drug Eloctate

[riky]

U.S. FDA approves Biogen's hemophilia A drug Eloctate

By Toni Clarke WASHINGTON (Reuters) - The U.S. Food and Drug Administration said on Friday it approved Biogen Idec Inc's long-lasting hemophilia A drug, Eloctate, adding another product to the company's nascent portfolio of drugs for non-malignant blood disorders. The FDA's ruling followed its approval in March of Biogen's hemophilia B treatment, Alprolix. Biogen developed both drugs with Swedish Orphan Biovitrum AB, or Sobi, and expects the products to form the basis of a new non-malignant blood disorder portfolio. "We see Alprolix and Eloctate as the anchor tenants in a growing franchise," said Douglas Williams, Biogen's head of research and development.

Source: You are not allowed to view links. Register or Login